The Ensign Group: UBS Raises PT to $205, Maintains Buy Rating

The Ensign Group: UBS Raises PT to $205, Maintains Buy Rating

UBS Group has raised its price target for The Ensign Group, Inc. (ENSG) to $205, maintaining a Buy rating. The updated target represents a potential upside of 17.8% from the current stock price, according to the latest research report from UBS Group [1].

The Ensign Group, Inc. operates in the skilled nursing, senior living, and rehabilitative care services sector. The company's shares have been trading at $172.73 as of the latest update. The stock's recent performance has been driven by strong quarterly earnings and positive analyst sentiment.

UBS Group's decision to raise the price target is based on the company's solid financial performance and the potential for future growth. The Ensign Group reported a quarterly revenue of $1.15 billion and a net profit of $1.26 per share for the last quarter, surpassing analysts' estimates [1].

Analysts have generally been optimistic about The Ensign Group's prospects. The consensus rating among analysts is a Moderate Buy, with an average target price of $178.94 [1]. Several major financial institutions, including Royal Bank Of Canada, Jefferies Financial Group, and Stifel Nicolaus, have recently upgraded their ratings on The Ensign Group's stock [1].

In addition to the financial performance, The Ensign Group's corporate insider activity has also been positive. Over the past quarter, there has been an increase in insiders buying shares of the company, indicating a bullish sentiment among key stakeholders [1].

UBS Group's updated price target reflects the company's strong fundamentals and the positive outlook from analysts. The Ensign Group's ability to deliver consistent earnings growth and maintain its market position in the healthcare sector makes it an attractive investment opportunity.

References:
[1] https://www.marketbeat.com/instant-alerts/heico-nysehei-price-target-raised-to-37500-at-ubs-group-2025-08-27/